ARCUTIS BIOTHERAPEUTICS, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $101.35 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $43.30M, a 52.22% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-06-30 was $60.65M, a 4.69% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-03-31 was $68.47M, a 11.37% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-12-31 was $57.28M, a 2.28% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $288.78M, a 28.96% decline from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $406.50M, a 15.66% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $351.47M, a 61.56% increase from fiscal 2021.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2021 was $217.55M, a 122.90% increase from fiscal 2020.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $101.35M 10-Q · filed 2026-08-05 | |||
| 2025-09-30 | $43.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $103.95M derived: sum of 2 quarters · filed 2026-08-05 | $172.42M 10-Q · filed 2025-10-28 | $229.69M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $60.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $129.12M 10-Q · filed 2026-08-05 | $186.40M derived: sum of 3 quarters · filed 2026-08-05 | $277.01M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $68.47M 10-Q · filed 2025-05-06 | $125.74M derived: sum of 2 quarters · filed 2025-05-06 | $216.36M derived: sum of 3 quarters · filed 2025-10-28 | $280.00M derived: sum of 4 quarters · filed 2025-10-28 |
| 2024-12-31 | $57.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $147.89M derived: sum of 2 quarters · filed 2025-10-28 | $211.53M derived: sum of 3 quarters · filed 2025-10-28 | $288.78M 10-K · filed 2025-02-25 |
| 2024-09-30 | $90.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $154.25M derived: sum of 2 quarters · filed 2025-10-28 | $231.51M 10-Q · filed 2025-10-28 | $287.51M derived: sum of 4 quarters · filed 2025-10-28 |
| 2024-06-30 | $63.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $140.89M 10-Q · filed 2025-08-06 | $196.89M derived: sum of 3 quarters · filed 2025-08-06 | $264.89M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $77.25M 10-Q · filed 2025-05-06 | $133.25M derived: sum of 2 quarters · filed 2025-05-06 | $201.25M derived: sum of 3 quarters · filed 2025-05-06 | $336.25M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $56.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $124.00M derived: sum of 2 quarters · filed 2025-02-25 | $259.00M derived: sum of 3 quarters · filed 2025-02-25 | $406.50M 10-K · filed 2025-02-25 |
| 2023-09-30 | $68.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $203.00M derived: sum of 2 quarters · filed 2024-11-06 | $350.50M 10-Q · filed 2024-11-06 | $430.91M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $135.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $282.50M 10-Q · filed 2024-08-14 | $362.91M derived: sum of 3 quarters · filed 2025-02-25 | $430.16M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $147.50M 10-Q · filed 2024-05-14 | $227.91M derived: sum of 2 quarters · filed 2025-02-25 | $295.16M derived: sum of 3 quarters · filed 2025-02-25 | $428.05M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $80.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $147.66M derived: sum of 2 quarters · filed 2025-02-25 | $280.55M derived: sum of 3 quarters · filed 2025-02-25 | $351.47M 10-K · filed 2025-02-25 |
| 2022-09-30 | $67.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $200.14M derived: sum of 2 quarters · filed 2023-11-03 | $271.06M 10-Q · filed 2023-11-03 | $343.06M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $132.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $203.81M 10-Q · filed 2023-08-08 | $275.81M derived: sum of 3 quarters · filed 2024-02-27 | $311.81M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $70.92M 10-Q · filed 2023-05-09 | $142.93M derived: sum of 2 quarters · filed 2024-02-27 | $178.93M derived: sum of 3 quarters · filed 2024-02-27 | $225.93M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $72.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $108.00M derived: sum of 2 quarters · filed 2024-02-27 | $155.00M derived: sum of 3 quarters · filed 2024-02-27 | $217.55M 10-K · filed 2024-02-27 |
| 2021-09-30 | $36.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $83.00M derived: sum of 2 quarters · filed 2022-11-08 | $145.55M 10-Q · filed 2022-11-08 | $169.55M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $47.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $109.55M 10-Q · filed 2022-08-04 | $133.55M derived: sum of 3 quarters · filed 2023-02-28 | $158.55M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $62.55M 10-Q · filed 2022-05-05 | $86.55M derived: sum of 2 quarters · filed 2023-02-28 | $111.55M derived: sum of 3 quarters · filed 2023-02-28 | $145.15M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $24.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $49.00M derived: sum of 2 quarters · filed 2023-02-28 | $82.60M derived: sum of 3 quarters · filed 2023-02-28 | $97.60M 10-K · filed 2023-02-28 |
| 2020-09-30 | $25.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $58.60M derived: sum of 2 quarters · filed 2021-11-04 | $73.60M 10-Q · filed 2021-11-04 | $75.60M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $33.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $48.60M 10-Q · filed 2021-08-05 | $50.60M derived: sum of 3 quarters · filed 2022-02-22 | $71.70M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $15.00M 10-Q · filed 2021-05-06 | $17.00M derived: sum of 2 quarters · filed 2022-02-22 | $38.10M derived: sum of 3 quarters · filed 2022-02-22 | $47.20M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $23.10M derived: sum of 2 quarters · filed 2022-02-22 | $32.20M derived: sum of 3 quarters · filed 2022-02-22 | $34.80M 10-K · filed 2022-02-22 |
| 2019-09-30 | $21.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $30.20M derived: sum of 2 quarters · filed 2020-11-05 | $32.80M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $9.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $11.70M 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $2.60M 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |